Key facts
- Citizens analyst Jason K. Song upgraded Rezolute to 'buy' from 'neutral'.
- The upgrade followed positive late-stage trial data for Rezolute's lead asset.
- Song cited potential for 'outsized returns' due to promising results.
Citizens analyst Jason K. Song has upgraded Rezolute to a 'buy' rating from 'neutral.' This upgrade comes after the company released positive late-stage clinical trial data for its lead asset. Song highlighted Rezolute's potential to achieve 'outsized returns' based on these promising trial results.